Skip to content

Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury

Phase IIb Study Assessing the Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells for Knee Cartilage Injury

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05016011
Enrollment
28
Registered
2021-08-23
Start date
2020-07-01
Completion date
2022-03-21
Last updated
2024-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Brief summary

In terms of the surgical treatment of the cartilage injury, various techniques and ways are created to repair or regenerate articular surface of synovial joint following traumatic damage or degeneration of the cartilage. The option for surgical treatments based on the size and depth of the cartilage knee injury may include knee debridement, radiofrequency, drilling, microfracture, mosaicplasty, allogenic osteochondral transplantation and autologous chondrocyte transplantation. The first two techniques mentioned have been used in treating the cartilage knee injury involving the partial defects meanwhile the latter techniques have been used for Grade III and IV cartilage defects based on ICRS. However, most of the surgical options up only provide more of Type I collagen rather than Type II collagen. The available treatments are more symptomatic rather than preventive or regenerative. Stem cell has big potential in this area where it has ability to differentiate to cartilage. As allogeneic umbilical cord blood MSCs are readily available and can be administered immediately, this study therefore aims to prove the efficacy of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treating large defects knee injury. The study is a prospective, randomized controlled, open label, phase IIb clinical trial, involving 50 patients with large defects of cartilage injury for follow-up duration of 24 months. Patients will be assigned into 2 arms; Arm A - 25 subjects will receive Chondrocell-EX (UC-MSCs) and Arm B - 25 subject will receive marrow cellution. All patients will undergo debridement prior to receiving their assigned treatment. The patients will be assessed on KOOS, IKDC, VAS and MRI.

Interventions

Human umbilical cord-derived mesenchymal stem cells

PROCEDUREMarrow cellution

Patients will undergo marrow cellution surgical procedure.

Sponsors

Universiti Kebangsaan Malaysia Medical Centre
CollaboratorOTHER
Cytopeutics Sdn. Bhd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Men and women aged between 18 and 65 years. 2. Patients diagnosed to have ICRS Grade 3 or 4 cartilage lesions based on the MRI scans of the affected knee. 3. Presence of knee swelling, pain, stiffness, or knee mechanical symptoms resulting from cartilage lesions. 4. All subjects must also satisfy at least 1 of the following inclusion criteria. * Isolated knee articular cartilage lesion (single lesion) estimated to be ≥1.0 cm2 as demonstrated on MRI scanning. * Multiple knee articular cartilage lesions (multiple lesions) with at least 1 lesion estimated to be ≥1.0 cm2 as demonstrated on MRI scanning. * Bipolar cartilage defects demonstrated on MRI scanning with at least 1 articular surface lesion to be ≥1.0 cm2. * One or more cartilage defects involving the patella-femoral joint as demonstrated on MRI scanning with at least 1 lesion ≥1.0 cm2. * One or more cartilage defects involving the tibio-femoral joint as demonstrated on MRI scanning with at least 1 lesion ≥1.0 cm2. * Previously failed cartilage repair procedures (i.e., microfracture, osteochondral autograft transplantation surgery (OATS), ACI) within 6 months.

Exclusion criteria

1. Preoperative flexion deformity greater than 10 degrees. 2. Significant cognitive impairment, non-ambulatory status or lower extremities amputation other than toes, serious illness or medication affecting operative risk or wound healing (e.g., steroid intake, anticoagulation). 3. Patient with high co-morbidity 4. Higher risk for postsurgical (e.g., bleeding disorder or taking anticoagulants except low-dose aspirin) or postsurgical infection (e.g., taking immune-suppressants, have a severe infection or a history of serious infection). 5. Significant peripheral vascular disease of the lower limbs as indicated by absent or substantially reduced dorsalis pedis or posterior tibial pulses. 6. Contraindications to sub-chondral drilling surgery. 7. Women who are pregnant or who are not able to use contraceptives 8. Known hypersensitivity (allergy) to hyaluronate or antibodies used for postsurgical prophylaxis. 9. Infections or skin disease affecting the area of the injection site or joint. 10. Intra-articular injections of hyaluronic acid in the target knee within the past 6 months before screening. 11. Intra-articular injections of corticosteroids in the target knee within the past 3 months before screening. 12. In the opinion of the investigators, the subjects have difficulty understanding or complying with the protocol procedures or requirements including follow up. 13. In the opinion of the investigators, the subject has any medical, psychiatric, or other condition for which the study would pose particular safety risks and/or unfavorably affect the risk-benefit balance of participation. 14. Presence of metallic implants, clips, or devices in the brain, eye, or spinal canal or implanted devices that are magnetically programmed that may affect the ability to perform MRI MOCART scoring. 15. Significant knee malalignment, varus or valgus deformity with more than 10 degrees, or instability associated with ligamentous knee injury.

Design outcomes

Primary

MeasureTime frameDescription
Recording of Adverse Events and Serious Adverse Events24 months
International Knee Documentation Committee (IKDC) score24 months
Knee Injury and Osteoarthritis Outcome Score (KOOS)24 months
Visual Analog Score (VAS)24 months
Immunohistochemistry (IHC)12 monthsIHC staining for generated cartilage

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026